In silico design of HDAC6 inhibitors with neuroprotective effects-Reference-Cited by-同舟云学术

In silico design of HDAC6 inhibitors with neuroprotective effects

Published:2021-11-16 Issue: Volume: Page:1-19
ISSN:0739-1102
Container-title:Journal of Biomolecular Structure and Dynamics
language:en
Short-container-title:Journal of Biomolecular Structure and Dynamics

Author:

Sixto-López Yudibeth¹²^ORCID,Gómez-Vidal José Antonio²^ORCID,de Pedro Nuria³^ORCID,Bello Martiniano¹^ORCID,Rosales-Hernández Martha Cecilia⁴^ORCID,Correa-Basurto José¹^ORCID

Affiliation:

1. Laboratorio de Modelado Molecular, Bioinformática y Diseño de fármacos, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico

2. Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Granada, Spain

3. Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Granada, Spain

4. Laboratorio de Biofísica y Biocatálisis, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México

Funder

CONACYT

SEP-CONACYT-ANUIES-ECOS Francia

Instituto Politécnico Nacional

COFAA-SIP/IPN. YSL

Publisher

Informa UK Limited

Subject

Molecular Biology,General Medicine,Structural Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07391102.2021.2001378

Reference66 articles.

1. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders

2. Combining docking and molecular dynamic simulations in drug design

3. HDAC inhibitors in kidney development and disease

4. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytotoxic evaluation of YSL-109 in a triple negative breast cancer cell line and toxicological evaluations;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-01-25

2. Drug repositioning to target NSP15 protein on SARS‐CoV ‐2 as possible COVID ‐19 treatment;Journal of Computational Chemistry;2021-03-13